Table 1.
Clinical characteristics of enrolled patients.
| Patient/Age Sex/Smoking | ECOG 1 | PFS 2 | Mutation | Stage | PD Location | Best Response | EKI |
|---|---|---|---|---|---|---|---|
| 1/59/M/− | 0 | 2.2 | L858R | T3N3M1b | MPE 3 | PD 4 | Erlotinib |
| 2/75/F/− | 1 | 5.2 | 19Del | T4N3M1a | lung | SD | Erlotinib |
| 3/82/M/− | 0 | 4.9 | L858R | T3N2 M1a | lung | SD | Afatinib |
| 4/56/M/+ | 0 | 2.0 | L858R | T4N3M1b | intestine | PD | Erlotinib |
| 5/53/M/+ | 1 | 1.0 | L858R | T4N3M1b | lung | PD | Afatinib |
| 6/53/F/− | 1 | 28.8 | L858R | T3N2 M1a | lung | SD | Gefitinib |
| 7/58/M/+ | 0 | 19.8 | L858R | T1N3M1b | brain | PR | Erlotinib |
| 8/80/M/+ | 1 | 16.0 | 19Del | T4N3M1b | liver | PR | Gefitinib |
| 9/64/M/+ | 1 | 12.6 | 19Del | T4N3M1b | brain | PR | Erlotinib |
| 10/73/F/− | 1 | 17.5 | L858R | T4N3M1b | MPE | PR | Erlotinib |
1 ECOG; Eastern Cooperative Oncology Group performance status, 2 PFS; Progress-free survival (months), 3 MPE; Malignant pleural effusion, 4 PR = partial response; SD = stable disease; PD = progressive disease.